(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis - Clinical Trial NCTNCT04910685

Business Opportunities for NCT04910685

Connect with principal investigators, study coordinators, and key decision makers for this PHASE2, PHASE3 trial studying investigational therapy for Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis.

Clinical Trial Information

Study Sponsor

Sponsor information available

Drug/Intervention

Study intervention details available

Therapeutic Area

Mastocytosis, Mastocytosis, Systemic

Study Phase

PHASE2, PHASE3

Study Status

RECRUITING

NCT Number

NCTNCT04910685

Find Contact Information

Access exclusive contact details for:

• Principal investigators and sub-investigators
• Study coordinators and research staff
• Site directors and facility contacts
• Sponsor representatives and CRO partners
• Business development professionals
• Clinical operations managers

Clinical Trial Locations

This study has 53 locations across United States, Australia, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom.

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

• Discover clinical trials before competitors
• Access exclusive contact information
• Track sponsor pipelines and opportunities
• Connect with decision makers directly
• Win more business partnerships